Shortly thereafter, folate radioconjugates began to also be considered for tumor-targeted radionuclide therapy that could overcome the main limitation of folate-conjugated chemotherapy, to which only cancer cells overexpressing FRα are sensitive. The gene discussed is FOLR1; the disease is cancer.